

Peptide-stimulated expansion of virus-specific T cells for preventative treatment after allogeneic stem cell transplantation

R. Gary¹, M. Aigner¹, A. Moosmann², and A. Gerbitz¹

¹Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany

²DZIF Research Group, Helmholtz Zentrum München, Munich, Germany

A phase I/IIa clinical trial was initiated to prevent or pre-emptively treat reactivation of CMV and EBV in patients after allogeneic hematopoietic stem cell transplantation (HSCT). For donor T-cell expansion, HLA class I and II matched peptides were chosen that cover antigens from all phases of CMV and EBV infection.

Introduction

Reactivation of latent herpesvirus infections represents a major clinical problem impacting outcomes in patients after allogeneic hematopoietic stem cell transplantation (HSCT). The adaptive immune system, especially T cells, plays an important role in the control of latent herpes virus infections. After allogeneic HSCT, adaptive immunity is severely compromised, resulting in frequent reactivation of cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Several groups worldwide have demonstrated high efficacy of adoptively transferred CMV- or EBV-specific T cells (1, 2). Therefore we aimed at overcoming the deficiency of CMV/EBV-protective T cells during the early phase of immune reconstitution after allogeneic HSCT by preventative adoptive transfer of peptide-stimulated CD4+ and CD8+ T cells.

For T-cell expansion, we selected HLA class I and II matched peptides and created peptide pools for CMV and EBV (3) (JPT Peptide Technologies). Peripheral blood mononuclear cells (PBMCs) from G-CSF-mobilized CMV/EBV-seropositive stem cell donors serve as T-cell source and allow for rapid expansion after stem cell transplantation. Using HLA-matched peptides for T-cell expansion allows for defined quality control by flow cytometry using peptide-loaded HLA multimers.

Based on preclinical data on T-cell expansion and the approval for a manufacturing license by the local governmental authority, a clinical trial phase I/IIa protocol was granted by the German federal authority Paul-Ehrlich-Institute. The clinical trial is focused on safety as this is a first-in-human study. The trial aims at a preventative/preemptive adoptive T-cell therapy in patients after allogeneic HSCT. Expanded T cells can be applied as early as day 30 after allogeneic HSCT at a dose of 5×10^4 CD3+ T cells/kg bodyweight. The adoptive transfer can be repeated twice in case no GvHD occurs within 30 days after the previous transfer. In addition to safety, the protocol aims at demonstrating efficacy. Therefore a randomized control group without treatment was included in the trial. As secondary endpoints reactivation of CMV and EBV and in addition the defined daily dose of antiviral medication for both viruses will be monitored. Furthermore, the reconstitution of CMV/EBV-specific T-cell immunity will be assessed during the observation period until day 204 after allogeneic HSCT.

Materials & Methods

Selected CMV- and EBV-derived **Clinical Grade Peptides** (9- to 15mers) were synthesized and pooled by JPT Peptide Technologies. For each virus, pools of 17 peptides (10 restricted through HLA class I, 7 restricted through HLA class II) were generated. The peptides have different HLA restrictions, such that approximately 80% of the European population is covered by at least one matched peptide from each virus. To ensure efficacy, for HLA class I only peptides that were shown to elicit responses in a majority of donors with the relevant HLA were included.

Lyophilized pools are ready-to-use in the GMP-conform manufacturing process. For

peptide stimulation, T-cells are obtained as PBMC as a small fraction of the G-CSF-mobilized stem cell graft. After initial cryopreservation, PBMC are stimulated with the two peptide pools in two separate fractions for two hours and washed. Pooled PBMC are then transferred into a closed bag system and expanded over 9 days. On day 9 after peptide stimulation, T cells are harvested and aliquoted.

To test functionality of expanded T cells, further analyses comprise flow cytometry of HLA-multimer-binding cells and intracellular IFN- γ detection upon restimulation with peptide pools. In addition, the TCR repertoire of the T-cell product will be analyzed by TCR- β chain next-generation sequencing to identify long living T cells within the product and the host after adoptive transfer.




Figure 1: Expansion of CMV (top panel) and EBV (bottom panel) specific T cells from G-CSF mobilized stem cells using HLA matched peptides. Stimulation was performed on day 0 followed by a 9 day expansion period without any further stimulation. A total of 33,28% specific T cells was achieved (16,79% CMV, 16,49% EBV) using HLA multimer staining.

Results

Stimulation of PBMC from G-CSF-mobilized allogeneic donors using two separate peptide pools for CMV and EBV results in a strong expansion of CMV- and EBV-specific T cells after 9 days of cultivation. As shown for HLA A*02:01-positive donors in Figure 1,

Clinical Peptides & Pools

the expansion of HLA-multimer binding T cells ranges from 7.5 to more than 100 fold.

PBMC from G-CSF-mobilized or non-mobilized donors can be used as starting material for T-cell expansion. By peptide stimulation, naïve T cells are efficaciously depleted, while effector and effector memory cells are expanded. Thus, the risk of GvHD after adoptive transfer is minimized, since alloreactive cells are largely derived the naïve T-cell compartment. Analysis of the peptide stimulated T-cell product using next generation sequencing of the TCR V-beta repertoire (4) demonstrated that only a limited number of T-cell receptors with specificity for each peptide was found within the product, which further increases the safety profile.

Discussion & Conclusions

With the current manufacturing protocol, CMV/EBV specific T-cells can be expanded in a GMP compliant fashion. This is mandatory for clinical trials within the EU legislation. The protocol allows for stringent quality control of the T-cell product. Our exclusive use of defined clinical grade peptides with known HLA class I and II restrictions will make it possible to use HLA class I multimers (and potentially class II multimers) for a comprehensive quantitative analysis of the specific T-cells in the product, and to track them in patients especially on a molecular level by next generation TCR V-beta sequencing. Since we avoid the use of hundreds to thousands of potentially irrelevant peptides, as for example provided by using overlapping peptides for stimulation, we decrease the probability that T-cells with unwanted specificities that accidentally cross-react with some of these peptides. Activation of T cells by peptide stimulation seems to be an important factor for the efficacy of the product as T cells will be adoptively transferred at an early stage after allogeneic HSCT and therefore will have to survive in a host treated with immunosuppressive agents such as Cyclosporine A. Moreover, it is very likely that our specificities of choice will be more efficaciously activated if the number of potentially competing peptides in the loading reaction is limited. Still, it is important to include peptides from a range of antigens from different phases of viral replication.

The manufacturing process has so far included a limited number of HLA allotypes, but can be extended to other specificities for which defined peptides become available. Thus, this protocol is a versatile platform for manufacturing T-cells with specificity for foreign antigens in the setting of allogeneic stem cell transplantation.

References

1. "Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for Adenovirus, EBV and CMV after allogeneic hematopoietic stem cell transplantation" Gerdemann *et al.*, Molecular Therapy (2013)
2. "Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells" Mackinnon *et al.*, Blood Cells, Molecules and Diseases (2008)
3. "Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells" Moosmann *et al.*, Blood (2010)
4. "Donor CD4 T-cell Diversity Determines Virus Reactivation in Patients After HLA-Matched Allogeneic Stem Cell Transplantation" Ritter J *et al.*, Am J Transplant. (2015)

The Authors



Dr. Andreas Moosmann
DZIF Research Group,
Helmholtz Zentrum
München, Munich,
Germany



Dr. Regina Gary
regina.gary@uk-erlangen.de
Department of Medicine 5
Hematology/Oncology
University Hospital Erlangen,
Germany



Dr. Michael Aigner
michael.aigner@uk-erlangen.de
Department of Medicine 5
Hematology/Oncology
University Hospital Erlangen
Germany



Prof. Dr. Armin Gerbitz
armin.gerbitz@uk-erlangen.de
Department of Medicine 5
Hematology/Oncology
University Hospital Erlangen
Germany

The Company

JPT Peptide Technologies is an ISO 9001:2015 certified provider of innovative peptide solutions for: cell therapy, cellular and humoral immune monitoring, seromarker discovery & validation, vaccine target discovery, peptide lead identification & optimization, targeted proteomics, and enzyme profiling.

Contact us for further information!

email: peptide@jpt.com
phone: +49 30 6392 7878

Please visit us online at:
<https://www.jpt.com>

Clinical Peptide & Pools

Based on knowledge and experience from research collaborations and quality audits by external laboratories and certification bodies, JPT established an enhanced production environment for Clinical peptides in addition to our RUO custom peptide synthesis and specialty synthesis units. The production environment for individual Clinical Peptides and Peptide Pools meets the more stringent product requirements of cellular therapy as well as vaccine & drug development.

Visit our webpage:

<https://www.jpt.com/clinical-peptides-pools/15>